Our Epibase® platform of in silico immunoprofiling services and in vitro cellular assays predict and compare the immunogenicity risk potential of your biotherapeutic candidates and over 500 known protein sequences. Epibase® in silico and in vitro platforms provide a comprehensive immunogenicity assessment package.
Designed for a wide range of targets:
Epibase® in silico (IS) is a T-cell epitope screening platform that analyzes and predicts the potential immunogenicity of proteins.
Our Epibase® in vitro platform directly measures the immune response induced by the protein in peripheral blood mononuclear cells (PBMCs) and can also assess potential off-target binding to healthy cells and immune activation (immunotoxicity). The platform can also be used to assess the impact of a process change or product and process-related impurities on the immunogenicity risk.
Understanding the immune response against your leads in a fully human in vitro system during early development will allow you to manage potential safety risks prior to embarking on clinical trials.
The Epibase® in vitro assays use human peripheral blood mononuclear cells (PBMCs) and in some cases combined with other healthy human tissue cells provides researchers with a human in vitro system to more closely mimic the potential immune response of a patient in the clinic. Whole blood and leukopaks are collected at clinical sites adhering to ethically approved protocols.